Nivolumab and rituximab in treatment-naive follicular lymphoma: the phase 2 1st FLOR study.

ABSTRACT:

Abstract

Follicular lymphoma (FL) outcomes are influenced by host immune activity. CD20-directed therapy plus programmed cell death 1 inhibition (PD-1i) increases T-cell tumor killing and natural killer cell antibody-dependent cell cytotoxicity. Mounting evidence supports immune priming using PD-1i before cancer directed agents. Our multicenter, phase 2 1st FLOR study enrolled 39 patients with previously untreated advanced-stage FL to receive 4 cycles of nivolumab (240 mg), then 4 cycles of 2-weekly nivolumab plus rituximab 375 mg/m2 (induction), then 1 year of monthly nivolumab (480 mg) plus 2 years of 2-monthly rituximab maintenance. Participants with complete response (CR) after nivolumab priming continued nivolumab monotherapy. The primary end point was toxicity during inductio

SUBMITTER: Barraclough A 

PROVIDER: S-EPMC11960644 | biostudies-literature | 2025 Mar

REPOSITORIES: biostudies-literature